Protara Therapeutics, Inc. TARA
3.28
(0.07)
(2.09%)
as of 25 Sep
- Market cap
- $198.0M
- P/E
- 0.0×
Follow TARA
| Dec '19 | Jan '20 | Dec '20 | Jan '21 | Dec '21 | Jan '22 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
0.23 | 58.13 | 58.13 | 21.66 | 21.66 | 15.01 | 15.01 | 11.17 | 15.71 | 14.58 |
Net Debt/EBITDA |
0.07 | 4.92 | 4.91 | 1.97 | 2.05 | 2.26 | 2.42 | 1.50 | 3.44 | 2.38 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.64 | 0.69 | 0.69 | 0.73 | 0.73 | 0.40 | 0.40 | 0.93 | 0.80 | 0.98 |
Capex/Depreciation |
(29.69) | 0.00 | (8.58) | 0.00 | (0.21) | 0.00 | 0.00 | 0.44 | 0.18 | 0.11 |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 367.95% | (34.48%) | (17.05%) | (26.17%) | (29.18%) | (49.96%) | (64.61%) | (47.44%) | (37.88%) | (31.60%) | |
| (640.23%) | (33.25%) | (16.72%) | (25.15%) | (27.38%) | (46.14%) | (58.22%) | (42.05%) | (34.25%) | (29.39%) | |
ROIC |
0.00% | 0.00% | (70.36%) | 0.00% | (41.99%) | 0.00% | (236.63%) | (994.46%) | 0.00% | (98.74%) |
Return on Tangible Assets |
367.95% | (20.25%) | (20.25%) | (48.36%) | (52.19%) | (74.71%) | (80.43%) | (63.30%) | (27.49%) | (38.47%) |
Average Days of Receivables |
— | — | — | — | — | 0.00 | — | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.15 | 0.15 | 0.17 | 0.17 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | — | 0.00% | — | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(2.13) | (3.24) | (3.36) | (3.07) | (3.12) | (2.35) | (2.36) | (3.32) | (1.74) | (1.32) |
Cash per Share |
0.22 | 23.31 | 23.31 | 8.12 | 8.12 | 7.49 | 7.49 | 5.79 | 8.27 | 3.63 |
Shareholders Equity per Share |
(0.83) | 27.54 | 27.54 | 14.41 | 14.41 | 9.07 | 9.07 | 6.03 | 8.12 | 4.59 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.83) | 27.54 | 27.54 | 14.41 | 14.41 | 9.07 | 9.07 | 6.03 | 8.12 | 4.59 |
Free Cash Flow |
(5.49) | (23.41) | (24.29) | (34.50) | (35.10) | (26.46) | (26.58) | (37.60) | (35.87) | (56.46) |
Working Capital |
(2.59) | 166.52 | 166.52 | 88.81 | 88.81 | 80.41 | 80.41 | 62.56 | 161.19 | 148.57 |
Capital Expenditures |
(0.47) | (0.88) | (0.88) | (0.60) | (0.60) | (0.12) | (0.12) | (0.04) | (0.06) | (0.09) |
Net Current Asset Value |
(2.59) | 165.52 | 165.52 | 82.43 | 82.43 | 74.94 | 74.94 | 58.07 | 157.84 | 146.45 |
| Other line items | ||||||||||
Quick Ratio |
0.17 | 57.86 | 57.86 | 21.23 | 21.23 | 14.70 | 14.70 | 10.67 | 15.54 | 14.22 |
Depreciation/Fixed assets |
0.03 | 0.16 | 0.08 | 0.13 | 1.69 | 0.03 | 20.27 | (0.08) | (0.34) | (1.16) |
Cash ROIC |
349.74% | (6.70%) | (6.70%) | (17.14%) | (14.31%) | (18.41%) | (15.04%) | (29.02%) | (10.92%) | (16.23%) |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | — | 0.00 | — | 0.00 | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | — | 0.00 | — | 0.00 | — | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1.94) | (3.24) | (3.24) | (3.07) | (3.07) | (2.35) | (2.35) | (3.31) | (1.74) | (1.32) |
Capex per Share |
(0.18) | 0.00 | (0.12) | 0.00 | (0.05) | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 |
Average Payables |
0.72 | 0.82 | 0.91 | 0.93 | 0.95 | 1.27 | 1.59 | 2.01 | 3.43 | 3.95 |
Average Assets |
1.22 | 102.19 | 203.16 | 187.88 | 172.60 | 142.94 | 113.29 | 96.12 | 130.20 | 195.46 |
Average Common Equity |
(2.13) | 98.56 | 199.24 | 180.58 | 161.91 | 132.00 | 102.08 | 85.20 | 117.73 | 181.77 |
Capex to Sales |
0.00 | — | 0.00 | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates